All In Biotech

Drug Trial Radar · NCT04213261

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

6

Actual

Start

Jun 9, 2020

Primary completion

Jan 17, 2023

Study completion Jul 2037

Sponsor

Lead sponsor
Castle Creek Biosciences, LLC.Industry
Sponsor type
Industry
First posted
Dec 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD

Conditions

  • Recessive Dystrophic Epidermolysis Bullosa

Interventions

  • FCX-007 (dabocemagene autoficel; see below for FCX-007 description)Biological

    FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Wound Closure of the First Wound Pair at Week 24Time frame: Week 24

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Solutions Through Advanced Research, Inc.

    Jacksonville, Florida

  • Mayo Clinic

    Rochester, Minnesota

  • Dell Children's Medical Group

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.